Company Performance Metrics
- Adrian Stecyk: CEO
Myrtelle is a gene therapy company that offers clinical trials for the treatment of rare monogenetic disorders. It helps in addressing an array of diseases with white matter involvement that includes demyelinating diseases and ASPA-associated disorders with rare CNS diseases. It also helps healthcare professionals to develop and deliver novel
treatments for devastating disorders of the central nervous system and transform the treatment of neurological diseases that improve the quality of life and longevity.
The company's mission is to develop and deliver novel treatments for devastating disorders of the central nervous system, beginning with its lead program, gene therapy treatment for Canavan disease.
It was founded in 2020 and is headquartered in Wakefield, Massachusetts.
